quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:16·3d
SECFiling
Alto Neuroscience Inc. logo

SEC Form EFFECT filed by Alto Neuroscience Inc.

ANRO· Alto Neuroscience Inc.
Health Care
Original source

Companies

  • ANRO
    Alto Neuroscience Inc.
    Health Care

Recent analyst ratings

  • Jan 5UpdateChardan Capital Markets$30.00
  • Nov 17UpdateBTIG Research-
  • Sep 29UpdateChardan Capital Markets$15.00
  • Oct 23UpdateWedbush$4.00
  • Oct 23UpdateRodman & Renshaw-
  • Sep 3UpdateWedbush$29.00

Related

  • PR2d
    Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
  • SEC13d
    SEC Form S-3 filed by Alto Neuroscience Inc.
  • SEC22d
    SEC Form 8-K filed by Alto Neuroscience Inc.
  • PR22d
    Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
  • SEC28d
    SEC Form DEFA14A filed by Alto Neuroscience Inc.
  • SEC28d
    SEC Form DEF 14A filed by Alto Neuroscience Inc.
  • SEC38d
    Alto Neuroscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
  • PR38d
    Alto Neuroscience Announces $120 Million Private Placement Financing
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022